Get the Stockscreener App
6.13
0.16%
0.010
After Hours:
5.96
-0.17
-2.77%
Insight Molecular Diagnostics Inc stock is traded at $6.13, with a volume of 38,752.
It is up +0.16% in the last 24 hours and up +82.99% over the past month.
Insight Molecular Diagnostics Inc is a pioneering diagnostics technology company whose mission is to democratize access to novel molecular diagnostic testing to improve patient outcomes. The Company's flagship technology quantifies a molecular biomarker known as donor-derived cell-free DNA (dd-cfDNA). It is also in the process of rebranding its RUO test kit, GraftAssure, as GraftAssureIQ, and rebranding its future in-vitro diagnostic (IVD) test kit as GraftAssureDx.
See More
Previous Close:
$6.12
Open:
$6.15
24h Volume:
38,752
Relative Volume:
0.81
Market Cap:
$175.44M
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-
EPS:
-
Net Cash Flow:
-
1W Performance:
-1.45%
1M Performance:
+82.99%
6M Performance:
+0.00%
1Y Performance:
+0.00%
1-Day Range:
$5.80
$6.20
1-Week Range:
$5.50
$6.31
52-Week Range:
$2.33
$6.76
Insight Molecular Diagnostics Inc Stock (IMDX) Company Profile
Name
Insight Molecular Diagnostics Inc
Sector
Industry
Phone
949-409-7600
Address
2 INTERNATIONAL PLAZA DR., SUITE 510, NASHVILLE
Compare IMDX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
IMDX
Insight Molecular Diagnostics Inc
|
6.13 | 175.15M | 0 | 0 | 0 | 0.00 |
|
TMO
Thermo Fisher Scientific Inc
|
565.24 | 212.23B | 43.74B | 6.58B | 6.11B | 17.31 |
|
DHR
Danaher Corp
|
213.83 | 151.20B | 24.27B | 3.50B | 5.02B | 4.8589 |
|
IDXX
Idexx Laboratories Inc
|
722.12 | 57.84B | 4.04B | 985.66M | 774.34M | 12.01 |
|
A
Agilent Technologies Inc
|
146.08 | 41.02B | 6.79B | 1.22B | 1.09B | 4.2644 |
|
IQV
Iqvia Holdings Inc
|
210.96 | 36.42B | 15.90B | 1.28B | 2.21B | 7.2842 |
Insight Molecular Diagnostics Inc Stock (IMDX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-28-25 | Initiated | Lake Street | Buy |
| May-24-22 | Downgrade | Stephens | Overweight → Equal-Weight |
| Mar-14-22 | Downgrade | KeyBanc Capital Markets | Overweight → Sector Weight |
| Jan-07-22 | Initiated | Stephens | Overweight |
| Jan-06-22 | Resumed | Piper Sandler | Overweight |
| Mar-17-21 | Resumed | Needham | Buy |
| Jan-07-21 | Upgrade | The Benchmark Company | Speculative Buy → Buy |
| Dec-16-20 | Upgrade | Piper Sandler | Neutral → Overweight |
| Nov-30-20 | Initiated | BTIG Research | Buy |
| Nov-10-20 | Initiated | KeyBanc Capital Markets | Overweight |
| Jul-30-20 | Reiterated | The Benchmark Company | Speculative Buy |
| Jul-01-20 | Downgrade | Piper Sandler | Overweight → Neutral |
| Jun-30-20 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| Jun-02-20 | Initiated | Needham | Buy |
| Feb-13-19 | Initiated | Piper Jaffray | Overweight |
| Jan-29-19 | Upgrade | Janney | Neutral → Buy |
| Dec-19-18 | Resumed | Lake Street | Buy |
View All
Insight Molecular Diagnostics Inc Stock (IMDX) Latest News
iMDx to Release Third Quarter 2025 Results on November 10 and Attend Stephens Annual Investment Conference the Following Week - The Manila Times
iMDx (NASDAQ: IMDX) schedules Q3 results for Nov 10, to attend Stephens conference - Stock Titan
What MACD trends signal for Insight Molecular Diagnostics Inc. (7OC0) stockEarnings Growth Report & Stepwise Entry/Exit Trade Alerts - newser.com
Is Insight Molecular Diagnostics Inc. (7OC0) stock a buy for dividend portfoliosWeekly Loss Report & Safe Capital Growth Tips - newser.com
Will Insight Molecular Diagnostics Inc. (7OC0) stock boost dividends furtherPortfolio Risk Report & Weekly High Potential Stock Alerts - newser.com
U.S., Europe, and Asia Pacific Molecular Diagnostics Market - openPR.com
Is Insight Molecular Diagnostics Inc. (7OC0) stock included in top ETFs2025 EndofYear Setup & Daily Growth Stock Investment Tips - newser.com
Analysts Offer Insights on Healthcare Companies: Align Tech (ALGN), TransMedics Group (TMDX) and Opko Health (OPK) - The Globe and Mail
Insight Molecular Diagnostics Advances Kidney Transplant Monitoring with New Study - TipRanks
Is Insight Molecular Diagnostics Inc. (7OC0) stock dividend growth reliablePortfolio Update Report & Weekly Setup with High ROI Potential - newser.com
On the Move: Oct. 21, 2025 - Nashville Post
BillionToOne IPO (BLLN.US): Unique Financial Profile For Molecular Diagnostics Company, Strong Buy - Smartkarma
US Market Wrap: What earnings margins imply for Insight Molecular Diagnostics Inc. (7OC0) stockWeekly Investment Summary & Technical Buy Zone Confirmation - Trung tâm Dự báo KTTV quốc gia
What earnings margins imply for Insight Molecular Diagnostics Inc. (7OC0) stock2025 Bull vs Bear & Comprehensive Market Scan Insights - Trung tâm Dự báo KTTV quốc gia
Returns Recap: Will Insight Molecular Diagnostics Inc. (7OC0) stock maintain strong growthWeekly Risk Report & Consistent Profit Trade Alerts - Trung tâm Dự báo KTTV quốc gia
Insight Molecular Diagnostics names Steven Tahmooressi as VP, marketing - Medical Buyer
Insight Molecular Diagnostics appoints Steven Tahmooressi as VP of Marketing - Investing.com Nigeria
Imdx welcomes new VP Marketing to prepare for commercial transplant assay launch - MarketScreener
iMDx Welcomes New VP Marketing to Prepare for Commercial Transplant Assay Launch - GlobeNewswire
Will Insight Molecular Diagnostics Inc. (7OC0) stock attract long term capital inflowsQuarterly Profit Report & Accurate Technical Buy Alerts - newser.com
Bullish Insight Molecular Diagnostics Insiders Rewarded As Their Investment Rises To US$4.85m - simplywall.st
Insight Molecular Diagnostics Inc.'s (NASDAQ:IMDX) large hedge funds owners must be happy as stock continues to impress, up 12% over the past week - Yahoo Finance
iMDx Reports Kidney Transplant Patient Achieved ‘Immune Reset’ with Novel Therapy and GraftAssure Monitoring - Sahm
Insight Molecular Diagnostics stock rises after transplant study publication - Investing.com
Insight Molecular Says GraftAssure Assay Helped Avoid Overtreatment in Kidney Transplant Patient - MarketScreener
Insight Molecular Diagnostics Inc Stock (IMDX) Financials Data
There is no financial data for Insight Molecular Diagnostics Inc (IMDX). Check out other stocks for more information.
Revenue
Net Income
Cash Flow
EPS
0.45%
6.29%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):